PSNL News and Press, Personalis Inc. From 03/23/22

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced it is presenting new data in scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2022 , which will be held in-person and online, April 8-13, 2022. ...

Personalis, Inc. (PSNL) Q4 2021 Earnings Conference Call February 24, 2022 5:00 PM ET Company Participants Caroline Corner – Investor Relations John West – President and Chief Executive Officer Aaron Tachibana – Chief Financial Officer Conference Call Participants Kevin D...

Personalis press release (NASDAQ:PSNL): Q4 GAAP EPS of -$0.45 beats by $0.05. Revenue of $20.68M (+2.5% Y/Y) in-line. Full year 2022 Outlook Total company revenue is expected to be approximately $67.0 million vs. $66.22M consensus Revenue from biopharma and all other customers, excluding the ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter and Recent Highlights Reported quarterly revenue of $20.7 million in the fou...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the Cowen 42 nd Annual Health Care Conference on Monday, March 7, 2022 at 2:10 p.m. Eastern Time. About Personalis Personalis, Inc. is a le...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a strategic collaboration with the Moores Cancer Center at University of California San Diego Health, a National Cancer Institute-designated Comprehensive Cancer Center, to support cli...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full-year 2021 financial results on Thursday, February 24, 2022. In conjunction with the release, the company will host a conference call and webcast th...

Personalis has seen a full boom and bust cycle again over the past year. Growth has slowed down and losses have increased, but fortunately the commercial side of the operations has seen a boost. Fundamentally, this remains a tough spot, but the cash position, modest sales multiple...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 15, 2022 at 2:00 p.m. Eastern Time. The webcast l...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2021. Personalis estimates revenue of approximately $20.7 million for the fourth ...